Glenmark acquires marketing rights to two generic products for pain from Lehigh Valley

By Lisa Kerner

Erie, Pa., May 2 - Glenmark Pharmaceuticals Ltd.'s wholly owned subsidiary, Glenmark Pharmaceuticals Inc. USA (GPI), signed a supply and marketing agreement with Lehigh Valley Technologies Inc. for the manufacturing and marketing of two liquid generic pharmaceutical products for the U.S. market.

These controlled substances for pain management have a cumulative market size of about $46 million with limited competition, according to a company news release.

Lehigh Valley will manufacture and supply the products to GPI, which will market them under the Glenmark label.

Glenmark said it expects to launch the products over a three month period beginning in August and will pay an initial milestone to Lehigh Valley for exclusive marketing rights.

Both companies will equally share profits on net U.S. sales.

Glenmark Pharmaceuticals is a Mumbai, India-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.